Evidence map›Paper›PMID 27694885›Full record

ReviewNature reviews. Microbiology2017

Emerging pathogenic links between microbiota and the gut-lung axis.

Kurtis F Budden, Shaan L Gellatly, David L A Wood, Matthew A Cooper, Mark Morrison, Philip Hugenholtz, Philip M Hansbro

Registry-linked trialAbstract readReview
PubMed Publisher
In one paragraph

Review in Nature reviews. Microbiology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04876833 (Characteristics of Intestinal Microbiome in the Progression of Early Chronic Obstructive Pulmonary Disease), which is not on this map. Cited by 964 papers, 8 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
964citing papers in PubMed, 8 pooled it
34.8field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT04876833 unknown statusnot on this mapstarted 2021, after this paper: background citation

Characteristics of Intestinal Microbiome in the Progression of Early Chronic Obstructive Pulmonary Disease

Typeobservational_patient_registrySponsorSecond Affiliated Hospital of Xi'an Jiaotong UniversityRan2021 to 2022Enrolled120ConditionsChronic Obstructive Pulmonary Disease
3 · Its place in the literature

Who cites it

964 citing papers in PubMed, 8 syntheses or guidelines pooled it, 1,509 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Pooled it
  8. Pooled it
  9. Trial
  10. Trial
  11. Frontiers in nutrition · 2026
    Trial
  12. Trial
  13. Trial
  14. Trial
  15. Review
  16. Review
  17. Article
  18. Article
  19. Review
  20. Review

904 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 3 institutions in 1 country.

Kurtis F BuddenPriority Research Centre for Healthy Lungs, University of Newcastle and Hunter Medical Research Institute, Newcastle, New South Wales 2305, Australia.
Shaan L GellatlyPriority Research Centre for Healthy Lungs, University of Newcastle and Hunter Medical Research Institute, Newcastle, New South Wales 2305, Australia.
David L A WoodAustralian Centre for Ecogenomics, School of Chemistry and Molecular Biosciences, The University of Queensland, Brisbane, Queensland 4072, Australia.
Matthew A CooperInstitute for Molecular Bioscience, The University of Queensland, Brisbane, Queensland 4072, Australia.
Mark MorrisonThe University of Queensland Diamantina Institute, Translational Research Institute, Brisbane, Queensland 4072, Australia.
Philip HugenholtzAustralian Centre for Ecogenomics, School of Chemistry and Molecular Biosciences, and the Institute for Molecular Bioscience, The University of Queensland, Brisbane, Queensland 4072, Australia; and The University of Queensland Diamantina Institute, Translational Research Institute, Woolloongabba, Queensland 4102, Australia.
Philip M HansbroPriority Research Centre for Healthy Lungs, University of Newcastle and Hunter Medical Research Institute, Newcastle, New South Wales 2305, Australia.
Hunter Medical Research Institute · AUUniversity of Queensland · AUTranslational Research Institute · AU

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The microbiota is vital for the development of the immune system and homeostasis. Changes in microbial composition and function, termed dysbiosis, in the respiratory tract and the gut have recently been linked to alterations in immune responses and to disease development in the lungs. In this Opinion article, we review the microbial species that are usually found in healthy gastrointestinal and respiratory tracts, their dysbiosis in disease and interactions with the gut-lung axis. Although the gut-lung axis is only beginning to be understood, emerging evidence indicates that there is potential for manipulation of the gut microbiota in the treatment of lung diseases.

Indexed as

BacteriaDysbiosisGastrointestinal MicrobiomeGastrointestinal TractHumansLungLung DiseasesRespiratory Tract Infections

Identifiers

PMID27694885
OpenAlexW2528396364

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.